Executive Team

Tony became CEO of NeoGenomics in April 2025. Prior to becoming CEO, he was a Board member for two years, serving as Chair of the Compensation committee and a member of the Audit and Technology committees. Tony has significant experience as a brand and marketing executive, with a focus on managing the interface between commercial and research and development aspects of an organization. Prior to serving as Chief Executive Officer of Innocoll Biotherapeutics, Tony was Executive Vice President, Commercial Operations of AstraZeneca (AZ), where he held global P&L responsibility for all of AZ’s brands and markets. Under Tony’s leadership, AZ commercialized 10 brands, each in excess of $1 billion in sales. Tony was responsible for MedImmune, AZ’s global biologics business. He also chaired the Commercial Investment Board, which identified and approved critical investments company-wide, including investments in plants, markets, and technology. Earlier in his career at AZ, Tony held various positions, including CEO of North America and VP of Sales, where he helped lead the integrations of Astra US, Astra Merck, and Zeneca. Prior to joining AZ, Tony spent 14 years with Berlex Laboratories in a variety of positions.

Jeff has over 32 years of finance experience in the healthcare services industry, having gained a well-rounded background from serving in finance roles at public companies of different sizes and at different growth stages in their lifecycle. While he has most recently served as Chief Financial Officer of Privia Health Group, Inc., a national physician enablement company, Jeff has also served as the Chief Financial Officer at three other organizations: HMS, a technology analytics and engagement solutions provider for government and commercial healthcare payers; AccentCare, a multi-state community-based healthcare delivery organization; and LIFEPOINT Health, a non-urban private hospital company operating 72 hospitals. Jeff also held various finance roles of increasing scope and responsibility at Tenet Healthcare Corporation.

Jeff received a B.A. in Finance/Accounting from the University of Colorado, Boulder, and an MBA from the University of Southern California.

When not working, he enjoys running, biking outside, hiking, and skiing with his family.

Warren Stone was appointed President and Chief Operating Officer of NeoGenomics in April 2025. He joined Neo in November 2022 as President, Clinical Services and later became Chief Commercial Officer.

Warren is a highly accomplished enterprise leader with extensive global experience in the life science and diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics (now QuidelOrtho).

As a hands-on leader, Warren championed the development of an organizational growth culture and digital transformation of systems and tools, including a hybrid/digital go-to-market deployment model, delivering productivity, margin expansion, and accelerated revenue growth. With an emphasis on customer experience, Warren’s team won an independent industry ServiceTrak™ award for the Best Pre/Post-Sales and Customer Success in 2021 and 2022.

Before joining Ortho Clinical, Warren served as Senior Vice President of Research Americas for MilliporeSigma, where he developed a commercial growth strategy, advancing the business 40% above the market. He also drove a cross-functional digital transformation to address customer needs, resulting in more than $200 million in incremental revenue in 2.5 years.

Gary Passman, Chief Culture Officer at NeoGenomics, is responsible for Neo’s strategy regarding its most important asset – its people. Cultivating an engaging culture focused on how the company works in support of all teammates and customers is critical to Neo’s success.

Gary has over 20 years of experience across several disciplines within the People & Culture, or Human Resources, function with both regional and global responsibilities. He joined Neo in early 2023.  Prior to joining Neo, he held numerous business partner and specialty area positions within HR across Johnson & Johnson.  Most recently Gary was the Head of Global People & Culture for Ortho Clinical Diagnostics from 2019 to 2022/

He holds a Bachelor of Arts degree in economics, as well as a master’s degree in human resource management, from Rutgers University.

Hutan most recently served as Chief Compliance Officer at Progenity, Inc., a women's health diagnostics company. A strategic and tactical executive, he counseled all levels of the organization, including the Board of Directors and executive management, on legal, compliance, and privacy issues facing the life sciences and biotech industry. Before joining Progenity in 2019, Mr. Hashemi was the Chief Compliance Officer at Genoptix, Inc., before the merger with NeoGenomics in 2018. Earlier in Hutan's legal career, he worked in private practice at law firms advising real estate and financial clients on a wide range of commercial, regulatory, corporate, litigation, and intellectual property matters.

Hutan's experience and background accentuate our unwavering commitment to achieving high compliance standards across our organization.

Dr. Andrew Lukowiak, Chief Innovation Officer serves as Neo’s Chief Innovation Officer (CIO). With nearly 25 years of experience in the clinical diagnostics industry, Andrew brings a wealth of experience, specializing in developing strategic programs and processes to introduce innovative, regulated products to market. 

As CIO, Andrew will lead our new Office of Innovation, driving cutting-edge research and development while ensuring continuous advancement and integration of new technologies. He will also oversee our Quality, Regulatory, and Clinical Studies teams. Most recently, he served as President and Chief Scientific Officer at TalisBiomedical, overseeing the menu expansion of the TalisOne™ platform. Prior to that, Andrew was the Chief Scientific Officer at Epigenomics AG, where he led the development of its next-generation blood-based colorectal cancer screening test. Earlier, as CEO of Millennium Health, a specialty CLIA laboratory, he successfully guided the organization through a strategic repositioning to drive future growth and success. Andrew has also held senior leadership roles at molecular diagnostics companies, including AltheaDx, GenMark Dx, Hologic, and Third Wave Technologies.

Andrew earned a B.S. in Biology from Penn State University and a Ph.D. in Genetics from the University of Georgia.

Ali Olivo has been serving as Executive Vice President, General Counsel and Business Development since January 1, 2024.

Ms. Olivo has more than 15 years of corporate business, M&A and legal expertise. She has been with NeoGenomics for five years representing NeoGenomics in acquisitions, as well as fundraising and governance activities. At Neo, she has also represented the company in various regulatory matters, including before CAP, OCR, and the OIG.

Prior to joining NeoGenomics, Ms. Olivo served as a Director at PricewaterhouseCoopers, LLP, negotiating incentives for numerous Fortune 500 clients. Ms. Olivo also spent many years at General Electric in various roles of increasing scope and responsibility, including Counsel, where she oversaw incentives negotiations, tax controversy, and government affairs.

Ali holds a B.A. from the University of Florida and a J.D. from Marquette University Law School

Most recently, Kareem served as Chief Transformation Officer at GeneDx, responsible for driving corporate strategy, corporate development, and emerging business initiatives to further accelerate the company’s growth. Prior to that, Kareem served as Chief Strategy Officer at Sema4, leading the development of their long term plan, spearheading their capital formation efforts and eventually helping to take the company public in 2021 before leading the merger with GeneDx to transform the company into a leading rare disease diagnostic testing company.

Prior to joining Sema4, Kareem was President and Chief Operating Officer at Apervita, Inc., overseeing its transformation to a product- and value-based care and quality measurement technology company. Kareem previously served as Chief Commercial Officer/EVP of Strategy and Business Development at SourceMed, a PE-backed healthcare IT and services company focused on delivering practice management technology solutions to the outpatient market, where he led a series of transactions that culminated in the sale and merger of the company with Surgical Information Systems.

Kareem also served as a Director in Dell’s Healthcare and Life Sciences division where he was responsible for managing a $180 million healthcare partner program. Before that, he held a number of executive roles in biotech and healthcare technology startups as well as leading the Information Based Medicine Commercial Group at IBM’s Healthcare Life Sciences group helping grow that business to $100 million in less than five years.

Kareem holds a BSc in Biochemistry and Molecular Biology with a minor in Computer Science from the University of British Columbia and an MBA with a concentration in Economics and Finance from the University of Chicago.

Dr. Montgomery is the Vice President of Medical Services and the Medical Director for the NeoGenomics North Carolina laboratory.  Dr. Montgomery joined NeoGenomics as the Director of Molecular Pathology Services in 2023, before taking on this current role in August 2024.  Prior to joining NeoGenomics, he was a molecular pathologist and medical director at Tempus Laboratories and, prior to that, Director of Molecular Hematopathology at the University of North Carolina.

Dr. Montgomery received his MD and PhD degrees from the University of North Carolina, where he also completed anatomic and clinical pathology residency training, as well as hematopathology and molecular genetic pathology fellowship training. He has authored over 60 peer-reviewed manuscripts and served on a number of national committees, including with the Association for Molecular Pathology and the American Society for Clinical Pathology.

Beth Eastland joined NeoGenomics in December of 2024 as the Senior Vice President of Enterprise Sales. Most recently, she served as General Manager for the commercial screening team at Exact Sciences and prior to that, served as the Vice President of Health Systems and Specialty, playing a key role in the development of the health system strategy at Exact Sciences including the development of health systems account manager and health technology teams, executing highly successful growth strategies to accelerate growth in key oncology and screening diagnostics. Her prior 30 years of experience in pharmaceuticals included responsibilities with broad leadership and strategic roles including sales, marketing, market access, strategy and operations in both the US and global markets at Merck from 1989-2015. She gained additional experience in senior leadership roles in mid-size and start-up companies with key launch brands before her transition to diagnostics in 2018. Beth brings significant experience in operating model transformation, commercial execution, strategic customer collaborations, and maximizing growth opportunities. She earned an undergraduate degree in Chemistry from Duke University and completed a certificate program in Science, Technology and Human Values.